DiaSorin S.p.A. (VIE:DIAS)
Austria · Delayed Price · Currency is EUR | Market Cap | 3.49B -30.9% |
| Revenue (ttm) | 1.17B -3.3% |
| Net Income | 141.62M -27.0% |
| EPS | 2.67 |
| Shares Out | n/a |
| PE Ratio | 24.63 |
| Forward PE | 16.41 |
| Dividend | 1.30 (1.98%) |
| Ex-Dividend Date | May 18, 2026 |
| Volume | n/a |
| Open | 65.84 |
| Previous Close | 66.04 |
| Day's Range | 65.84 - 66.30 |
| 52-Week Range | 54.24 - 95.12 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About DiaSorin
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine... [Read more]
Financial Performance
In 2025, DiaSorin's revenue was 1.20 billion, an increase of 0.81% compared to the previous year's 1.19 billion. Earnings were 155.62 million, a decrease of -17.27%.
Financial StatementsNews
DiaSorin Transcript: Investor Day 2026
The five-year plan targets 6%-8% annual revenue growth through specialty leadership in immunodiagnostics and molecular diagnostics, with a focus on innovation, automation, and U.S. expansion. Financial guidance includes margin expansion and EUR 1 billion free cash flow, while capital allocation prioritizes organic growth, dividends, and selective M&A.
DiaSorin Press release: FY 2026
DiaSorin issued a press release on May 20, 2026, disclosing material business information to investors.
DiaSorin Slides: FY 2026
DiaSorin has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 20, 2026.
DiaSorin Earnings Call Transcript: Q1 2026
Q1 2026 saw a 3% revenue decline at constant FX, mainly from weak flu season, China headwinds, and U.S. destocking, but immuno grew 1% and guidance for 5%-6% annual growth is maintained. Share buybacks and tariff changes impacted net debt and margins.
DiaSorin Earnings release: Q1 2026
DiaSorin released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
DiaSorin Slides: Q1 2026
DiaSorin has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
DiaSorin price target lowered to EUR 62 from EUR 65 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on DiaSorin (DSRLF) to EUR 62 from EUR 65 and keeps a Hold rating on the shares.
DiaSorin downgraded to Neutral from Buy at UBS
UBS analyst Kavya Deshpande downgraded DiaSorin (DSRLF) to Neutral from Buy with a price target of EUR 66, down from EUR 84. The firm sees modest risk to estimates and…
DiaSorin price target lowered to EUR 65 from EUR 74 at Deutsche Bank
Deutsche Bank analyst Jan Koch lowered the firm’s price target on DiaSorin (DSRLF) to EUR 65 from EUR 74 and keeps a Hold rating on the shares. Published first on…
DiaSorin price target lowered to EUR 60 from EUR 65 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on DiaSorin (DSRLF) to EUR 60 from EUR 65 and keeps an Equal Weight rating on the shares.
DiaSorin Earnings Call Transcript: Q4 2025
2025 saw modest revenue growth, strong immuno performance in North America, and strategic shifts in China amid VBP pressures. 2026 guidance anticipates 5%-6% revenue growth, with profitability impacted by product launches, FX, and ongoing macroeconomic headwinds.
DiaSorin Earnings release: Q4 2025
DiaSorin released its Q4 2025 earnings on March 20, 2026, summarizing the period's financial results.
DiaSorin Slides: Q4 2025
DiaSorin has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 20, 2026.
DiaSorin Annual report: Q4 2025
DiaSorin has published its Q4 2025 annual report on March 20, 2026.
DiaSorin price target raised to EUR 74 from EUR 71 at Deutsche Bank
Deutsche Bank analyst Jan Koch raised the firm’s price target on DiaSorin (DSRLF) to EUR 74 from EUR 71 and keeps a Hold rating on the shares. Published first on…
DiaSorin price target raised to EUR 65 from EUR 63 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on DiaSorin (DSRLF) to EUR 65 from EUR 63 and keeps an Equal Weight rating on the shares. Published first…
DiaSorin upgraded to Neutral from Underperform at BNP Paribas
BNP Paribas analyst Hugo Solvet upgraded DiaSorin (DSRLF) to Neutral from Underperform.
DiaSorin downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded DiaSorin (DSRLF) to Equal Weight from Overweight with a price target of EUR 63, down from EUR 99. The firm says macro headwinds continue to present earnings…
DiaSorin price target lowered to EUR 58 from EUR 68 at JPMorgan
JPMorgan lowered the firm’s price target on DiaSorin (DSRLF) to EUR 58 from EUR 68 and keeps an Underweight rating on the shares.
DiaSorin Earnings Call Transcript: Q3 2025
Revenues grew 3% year-over-year to EUR 900 million, with core business up 6% at constant FX. Immuno and molecular segments showed solid growth outside China, while LTG faced life science headwinds. 2025 guidance was revised to 5% ex-COVID revenue growth and 33% EBITDA margin.
DiaSorin Earnings release: Q3 2025
DiaSorin released its Q3 2025 earnings on November 5, 2025, summarizing the period's financial results.
DiaSorin Slides: Q3 2025
DiaSorin has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 5, 2025.
DiaSorin Earnings Call Transcript: Q2 2025
H1 2025 saw 5% revenue growth to EUR 619 million, with core business up 8% at constant FX and EBITDA margin at 35%. Immunodiagnostics and Molecular Diagnostics segments delivered strong growth, while China faced double-digit declines. 2025 guidance for 8% core revenue growth and 34% EBITDA margin is confirmed.
DiaSorin Earnings release: Q2 2025
DiaSorin released its Q2 2025 earnings on July 31, 2025, summarizing the period's financial results.
DiaSorin Quarterly report: Q2 2025
DiaSorin has published its Q2 2025 quarterly earnings report on July 31, 2025.